TORONTO – Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 – 17, 2010. The gene, abbreviated MTHFD1L, is located on chromosome six.
"Only recently have common variants in genes other than APOE been convincingly shown to be associated with a person's risk of developing late-onset Alzheimer's disease," said senior author Margaret Pericak-Vance, PhD, the principal investigator of the study and Director of the University of Miami Miller School of Medicine's John P. Hussman Institute for Human Genomics in Miami, Florida.
Researchers looked at gene variation throughout the human genomes of 2,269 people with late-onset Alzheimer's disease and 3,107 people without the disease through what's known as a genome-wide association study. Such studies involve looking at long stretches of DNA to identify small differences in the genetic sequence between people with and without Alzheimer's disease.
The study found that individuals with a particular variation in the gene MTHFD1L may be almost twice as likely to develop Alzheimer's disease as those people without the variation. "We are hopeful our identification of MTHFD1L as a risk gene for Alzheimer's disease will help us to better understand how this disease develops and potentially serve as a marker for people who may be at increased risk," said Adam Naj, PhD, with the University of Miami Miller School of Meidicne's John P. Hussman Institute for Human Genomics in Miami and the first author of the abstract reporting the discovery.
"Identifying this gene is important because the gene is known to be involved in influencing the body's levels of homocysteine, and high levels of homocysteine are strong risk factor for late-onset Alzheimer's disease," said Pericak-Vance. "In addition, variations of the MTHFD1L gene have been reported to possibly increase the risk of coronary artery disease. Since the function of blood vessels in the brain may affect Alzheimer's disease, this finding may also help us understand how homocysteine levels and blood vessel function in the brain affect Alzheimer's disease."
The World Health Organization estimates that there are currently 18 million people worldwide with Alzheimer's disease, and this figure is projected to nearly double to 34 million by 2025. There are currently at least five million Americans living with Alzheimer's disease today.
The study was supported by the National Institutes of Health and the National Institute on Aging. The research team responsible for the work includes collaborators Jonathan Haines, PhD, from Vanderbilt University Medical Center and Joseph D. Buxbaum, PhD with Mount Sinai School of Medicine.
The American Academy of Neurology's Annual Meeting is the world's largest gathering of neurologists with more than 2,300 scientific research presentations on brain disorders.
The American Academy of Neurology, an association of more than 22,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, stroke and migraine. For more information about the American Academy of Neurology, visit http://www.aan.com.
Dr. Pericak-Vance will be available for media questions during a press conference at 11:00 a.m. ET, on Tuesday, April 13, 2010, in Room 803B of the Metro Toronto Convention Centre in Toronto. Please contact Rachel Seroka, firstname.lastname@example.org, to receive conference call information for those reporters covering the press conference off-site.
Dr. Pericak-Vance is also available for advance interviews as well. Please contact Rachel Seroka, email@example.com, to schedule an advance interview.
Dr. Pericak-Vance is scheduled to present her late-breaking abstract at 7:30 a.m., ET, on Wednesday, April 14, 2010, in Room 808 of the Metro Toronto Convention Centre in Toronto.
To view non-late-breaking abstracts to be presented at the 2010 AAN Annual Meeting, visit http://www.aan.com/go/am10/science. Late-breaking abstracts will not be posted online in advance of the meeting and are embargoed until the date and time of presentation at the AAN Annual Meeting in Toronto or unless otherwise noted by the Academy's Media and Public Relations Department.